Fiedler, Mathias and Off, Alisa and Gaertner, Andreas and Brockhoff, Gero and Eichberger, Jonas and Gottsauner, Maximilian and Schuderer, Johannes G. and Maurer, Michael and Bauer, Richard J. and Gerken, Michael and Reichert, Torsten E. and Ettl, Tobias and Weber, Florian (2025) Increased PD-1/PD-L1 Immune Checkpoint Expression Is Associated With Oral Squamous Cell Carcinoma in Never-Smokers and Never-Drinkers. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 47 (3). pp. 822-831. ISSN 1043-3074, 1097-0347
Full text not available from this repository. (Request a copy)Abstract
Background This study aimed to explore the disparities in PD-1 and PD-L1 expression among oral squamous cell carcinomas (OSCCs) in individuals categorized as never-smokers/never-drinkers versus smokers/drinkers. Methods Immunohistochemical staining for PD-1 and PD-L1, along with PDCD1LG2/cen9 dual color probe analysis, was conducted on 130 OSCC specimens from both smoker/drinker and never-smoker/never-drinker cohorts. Associations between smoking/drinking status, clinicopathologic data, immunohistochemical antibody expression, fluorescence in situ hybridization, and survival outcomes were assessed. Results OSCC in never-smokers/never-drinkers exhibited significantly elevated PD-1 expression (p = 0.003), increased PD-L1-TPS expression (p = 0.044), and elevated PD-L1-CPS expression (p < 0.001). High PD-L1-ICS expression was more prevalent in never-smokers (p = 0.042). Moreover, never-smokers and never-drinkers demonstrated augmented PD-L1 gene copy numbers (p = 0.081 and p = 0.054, respectively). Increased PD-L1 gene copy number, particularly amplification, correlated with PD-L1-TPS (p = 0.039 and p < 0.001). Conversely, PD-L1 gene copy loss was associated with negative PD-L1-CPS (p = 0.023). Notably, positive PD-L1-CPS was significantly linked with improved overall survival (p = 0.023). Conclusions OSCC arising in never-smokers/never-drinkers exhibit heightened PD-1/PD-L1 signaling, suggesting potential efficacy of immune checkpoint therapy in this subgroup of tumors.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | TOBACCO SMOKING; OPEN-LABEL; HEAD; RECURRENT; DRINKING; CANCER; PEMBROLIZUMAB; NONSMOKING; never-drinkers; never-smoker; Oral squamous cell carcinoma; PD-1; PD-L1 |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Mund-, Kiefer- und Gesichtschirurgie Medicine > Lehrstuhl für Pathologie Medicine > Lehrstuhl für Urologie Medicine > Zentren des Universitätsklinikums Regensburg > Tumorzentrum e.V. |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 03 Mar 2026 07:51 |
| Last Modified: | 03 Mar 2026 07:51 |
| URI: | https://pred.uni-regensburg.de/id/eprint/63379 |
Actions (login required)
 |
View Item |
